From the Field
Are GLP-1s the next industry disruptor?
Some are predicting that GLP-1s could pose a disruptive threat to the medtech industry, as demand for medical devices and surgical procedures could be greatly reduced.
Taymour Tamaddon, Portfolio Manager, US Large Cap Growth Equity Strategy
Key Insights
  • While GLP‑1s have been around almost 20 years, they’ve recently been catapulted into the public domain due to their demonstrated effectiveness as a weight loss agent.
  • This success has led to speculation about broader impacts on the medtech industry, given its principal role in the treatment and management of obesity and its comorbidities.
  • Some are predicting that GLP‑1s pose a disruptive threat to the medtech industry, as demand for medical devices and surgical procedures could be greatly reduced.

Congratulations! You are now registered.

Start subscribing to receive email updates.

You have updated your email address.

An activation email has been sent to your new email address from T. Rowe Price.

Please click on the activation link in order to receive email updates.

You have an existing account

Click OK to view your subscriptions.

Preferred Website

Confirm

You are currently logged in to multiple T. Rowe Price websites.

You will need to log out below and log back in with your Advisor Dashboard credentials.

Log Out Now

You are now leaving the T. Rowe Price website.

T. Rowe Price is not responsible for the content of third party websites, including any performance data contained within them. Past performance cannot guarantee future results.

Cancel Go To Site